CD274 and non-small cell lung carcinoma: A comparative study, (Blueprint phase I and II projects) to assess the feasibility of harmonising the clinical use of these independently-developed commercially- and FDA-approved PD-L1 IHC assays for PD-L1 detection has been conducted for NSCLC.